Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$485 Mln
P/E Ratio
--
P/B Ratio
0.99
Industry P/E
--
Debt to Equity
0.07
ROE
-0.44 %
ROCE
-36.26 %
Div. Yield
0 %
Book Value
1.34
EPS
-0.39
CFO
$-373.06 Mln
EBITDA
$-478.67 Mln
Net Profit
$-743.48 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Standard Biotools Inc (LAB)
| -29.71 | 1.65 | -25.68 | -51.95 | -23.98 | -12.44 | -29.94 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Standard Biotools Inc (LAB)
| -20.66 | 88.89 | -34.67 | 72.41 | -59.63 | 46.05 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.50 | 10,541.60 | 14.73 | 12.69 | |
| 73.07 | 9,636.16 | 93.23 | 2.52 | |
| 162.63 | 8,533.78 | -- | -25.23 | |
| 298.25 | 10,783.83 | 774.36 | 1.2 |
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East,... Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California. Address: 2 Tower Place, South San Francisco, CA, United States, 94080 Read more
President, CEO & Director
Dr. Michael Egholm Ph.D.
President, CEO & Director
Dr. Michael Egholm Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Standard Biotools Inc (LAB) stood at $ 612 Mln as on 31-Dec-24
The share price of Standard Biotools Inc (LAB) is $1.23 (NYSE) and $1.23 (NASDAQ) as of 24-Apr-2025 16:00 EDT. Standard Biotools Inc (LAB) has given a return of -23.98% in the last 3 years.
Standard Biotools Inc (LAB) has a market capitalisation of $ 485 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Standard Biotools Inc (LAB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Standard Biotools Inc (LAB) and enter the required number of quantities and click on buy to purchase the shares of Standard Biotools Inc (LAB).
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California. Address: 2 Tower Place, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Michael Egholm Ph.D.. is Standard Biotools Inc (LAB), and CFO & Sr. VP is Dr. Michael Egholm Ph.D..
There is no promoter pledging in Standard Biotools Inc (LAB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Standard Biotools Inc (LAB) | Ratios |
|---|---|
|
Return on equity(%)
|
-43.75
|
|
Operating margin(%)
|
-77.39
|
|
Net Margin(%)
|
-79.62
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Standard Biotools Inc (LAB) was $0 Mln.
$-1.25
(
